FDA-cleared profile

DeepTek CXR Analyzer v1.0

DeepTek Medical Imaging Pvt Ltd · X-ray/Radiography · FDA-cleared (510(k))

Authorized purpose: Concurrent CADe support for identifying, categorizing, and highlighting suspicious regions of interest in the Lungs, Pleura, Cardiac, and Hardware categories on chest radiographs for radiologist review.

Clinical role
Concurrent-reader CADe detection, category classification, localization, and highlighting of suspicious chest-radiograph ROIs.
Images and patients
X-ray/Radiography · Chest: lungs, pleura, cardiac structures, and hardware
Key limitation
Keep in mind: The device is an adjunct and not the primary interpretation; radiologists must review the annotated and original unannotated images. It does not make treatment recommendations or provide a diagnosis and is not designed to detect conditions outside the four listed categories; the labeled population is adults and transitional adolescents treated as adults.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Concurrent CADe support for identifying, categorizing, and highlighting suspicious regions of interest in the Lungs, Pleura, Cardiac, and Hardware categories on chest radiographs for radiologist review.
  • Which images or clinical context are in scope?Modality: X-ray/Radiography Anatomy or clinical context: Chest: lungs, pleura, cardiac structures, and hardware Input: Adult frontal chest radiographs in DICOM format from adults and transitional adolescents aged 18 to under 22 years who are treated like adults.
  • Who uses it?Intended users: Radiologists.
  • What does the software produce?Output: A secondary-capture DICOM image containing the original radiograph, manufacturer/product/version information, color-coded bounding boxes for suspected Lungs, Pleura, Cardiac, or Hardware ROIs, or a 'No Suspicious ROI(s) Detected' message when no boxes are present; workflow errors are logged.
  • What is its most important limitation?Key limitation: The device is an adjunct and not the primary interpretation; radiologists must review the annotated and original unannotated images. It does not make treatment recommendations or provide a diagnosis and is not designed to detect conditions outside the four listed categories; the labeled population is adults and transitional adolescents treated as adults.

Clinical takeaway. Clinical role: Concurrent CADe support for identifying, categorizing, and highlighting suspicious regions of interest in the Lungs, Pleura, Cardiac, and Hardware categories on chest radiographs for radiologist review.

Evidence takeaway. Evidence from the reviewed source record: FDA packet: standalone testing used 3,000 scans (2,000 NIH and 1,000 Segmed) with three U.S. board-certified radiologists establishing majority ground truth. Image-level standalone sensitivity/specificity/AUROC by category were Lungs 0.903/0.937/0.971, Pleura 0.924/0.897/0.964, Cardiac 0.924/0.930/0.978, Hardware 0.947/0.947/0.980, and aggregate 0.926/0.933/0.974. ROI-level wAFROC-FOM was aggregate 0.920. The 300-image, 24-reader MRMC study from 13 U.S. hospitals found aggregate aided wAFROC-FOM 0.893 (95% CI 0.871-0.914) versus unaided 0.821 (0.791-0.852), p<0.0001; reader sensitivity/specificity were separate aided/unaided endpoints.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Concurrent CADe support for identifying, categorizing, and highlighting suspicious regions of interest in the Lungs, Pleura, Cardiac, and Hardware categories on chest radiographs for radiologist review.
  • Exact FDA submission
  • Checked 2026-09-09
Workflow role
Concurrent-reader CADe detection, category classification, localization, and highlighting of suspicious chest-radiograph ROIs.
  • Exact FDA submission
  • Checked 2026-09-09
Required input
Adult frontal chest radiographs in DICOM format from adults and transitional adolescents aged 18 to under 22 years who are treated like adults.
  • Exact FDA submission
  • Checked 2026-09-09
Output and clinician action
A secondary-capture DICOM image containing the original radiograph, manufacturer/product/version information, color-coded bounding boxes for suspected Lungs, Pleura, Cardiac, or Hardware ROIs, or a 'No Suspicious ROI(s) Detected' message when no boxes are present; workflow errors are logged.
  • Exact FDA submission
  • Checked 2026-09-09
Care setting
Radiologist chest-radiograph reading workflow; the clinical reader study used 13 U.S. hospitals, but the FDA packet does not define all facility types.
  • Exact FDA submission
  • Checked 2026-09-09
Intended users
Radiologists.
  • Exact FDA submission
  • Checked 2026-09-09
Limitations
The device is an adjunct and not the primary interpretation; radiologists must review the annotated and original unannotated images. It does not make treatment recommendations or provide a diagnosis and is not designed to detect conditions outside the four listed categories; the labeled population is adults and transitional adolescents treated as adults.
  • Exact FDA submission
  • Checked 2026-09-09
Evidence summary
FDA packet: standalone testing used 3,000 scans (2,000 NIH and 1,000 Segmed) with three U.S. board-certified radiologists establishing majority ground truth. Image-level standalone sensitivity/specificity/AUROC by category were Lungs 0.903/0.937/0.971, Pleura 0.924/0.897/0.964, Cardiac 0.924/0.930/0.978, Hardware 0.947/0.947/0.980, and aggregate 0.926/0.933/0.974. ROI-level wAFROC-FOM was aggregate 0.920. The 300-image, 24-reader MRMC study from 13 U.S. hospitals found aggregate aided wAFROC-FOM 0.893 (95% CI 0.871-0.914) versus unaided 0.821 (0.791-0.852), p<0.0001; reader sensitivity/specificity were separate aided/unaided endpoints.
  • Exact FDA submission
  • Checked 2026-09-09

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA packet: standalone testing used 3,000 scans (2,000 NIH and 1,000 Segmed) with three U.S. board-certified radiologists establishing majority ground truth. Image-level standalone sensitivity/specificity/AUROC by category were Lungs 0.903/0.937/0.971, Pleura 0.924/0.897/0.964, Cardiac 0.924/0.930/0.978, Hardware 0.947/0.947/0.980, and aggregate 0.926/0.933/0.974. ROI-level wAFROC-FOM was aggregate 0.920. The 300-image, 24-reader MRMC study from 13 U.S. hospitals found aggregate aided wAFROC-FOM 0.893 (95% CI 0.871-0.914) versus unaided 0.821 (0.791-0.852), p<0.0001; reader sensitivity/specificity were separate aided/unaided endpoints.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Reported sensitivity
Image-level standalone at the recommended operating threshold: Lungs 0.903 (95% CI 0.887-0.914); Pleura 0.924 (0.902-0.932); Cardiac 0.924 (0.890-0.952); Hardware 0.947 (0.936-0.955); Aggregate 0.926 (0.917-0.933).
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09

These are category- and aggregate-labeled standalone image-level endpoints; AUROC, wAFROC-FOM, and MRMC reader endpoints remain distinct.

Reported specificity
Image-level standalone at the recommended operating threshold: Lungs 0.937 (95% CI 0.927-0.948); Pleura 0.897 (0.879-0.911); Cardiac 0.930 (0.925-0.941); Hardware 0.947 (0.939-0.954); Aggregate 0.933 (0.925-0.938).
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09

These are category- and aggregate-labeled standalone image-level endpoints; aided/unaided reader specificity is a separate MRMC endpoint.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

DeepTek CXR analyzer v1.0 regulatory performance study summary

  • DesignStand-alone performance and reader study (ACR AI Central category)
  • PopulationAdult
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K231001
  • Samplen=3000
  • IndependenceIndependence not established

K231001

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K231001. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-09
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Adult frontal chest radiographs in DICOM format from adults and transitional adolescents aged 18 to under 22 years who are treated like adults.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-09 · FDA K231001: DeepTek CXR Analyzer v1.0

  2. Routing

    Source context, not route validation: The FDA packet describes configurable PACS connectivity using AE Title, IP address, listener and sender ports, DICOM chest-radiograph input from the configured PACS, and secondary-capture DICOM output returned to that PACS; it does not establish universal PACS/RIS/EHR compatibility.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-09 · FDA K231001: DeepTek CXR Analyzer v1.0

  3. AI processing

    Source context, not route validation: The exact FDA package describes the DeepTek CXR Analyzer platform as secure on-premise processing and delivery of chest radiographs. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "Platform Secure on-premise processing and Secure cloud-based processing and delivery of chest radiographs delivery of chest radiographs" … "Feature/ Proposed Device Predicate Device Function DeepTek CXR Analyzer Chest-CAD (K210666)". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA K231001: DeepTek CXR Analyzer v1.0

  4. Returned objects

    Source context, not route validation: A secondary-capture DICOM image containing the original radiograph, manufacturer/product/version information, color-coded bounding boxes for suspected Lungs, Pleura, Cardiac, or Hardware ROIs, or a 'No Suspicious ROI(s) Detected' message when no boxes are present; workflow errors are logged.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-09 · FDA K231001: DeepTek CXR Analyzer v1.0

  5. Viewer/worklist/report

    Unresolved route: A secondary-capture DICOM image containing the original radiograph, manufacturer/product/version information, color-coded bounding boxes for suspected Lungs, Pleura, Cardiac, or Hardware ROIs, or a 'No Suspicious ROI(s) Detected' message when no boxes are present; workflow errors are logged.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-09 · FDA K231001: DeepTek CXR Analyzer v1.0

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes the DeepTek CXR Analyzer platform as secure on-premise processing and delivery of chest radiographs. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Platform Secure on-premise processing and Secure cloud-based processing and delivery of chest radiographs delivery of chest radiographs" … "Feature/ Proposed Device Predicate Device Function DeepTek CXR Analyzer Chest-CAD (K210666)". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
The FDA packet describes configurable PACS connectivity using AE Title, IP address, listener and sender ports, DICOM chest-radiograph input from the configured PACS, and secondary-capture DICOM output returned to that PACS; it does not establish universal PACS/RIS/EHR compatibility.
  • Exact FDA submission
  • Checked 2026-09-09
Security
DeepTek's regulatory page states that its products and services are designed and developed with security as a high priority and claims compliance with global security standards and regulations including ISO 27001, GDPR, and HIPAA; the same page names CXR Analyzer among its US FDA 510(k)-cleared solutions.
  • Vendor-wide
  • Checked 2026-10-27

Vendor statement; no certificates read. Company-level statement applied to DeepTek Medical Imaging Pvt Ltd entries. Exact-release scope is not established.

Input or output interoperability

DICOM is explicitly referenced in the described input, output, or workflow.

exact submission · checked 2026-09-01

The model card does not establish every supported DICOM object, transfer method, or local interface.

Supported acquisition environment

Scanner manufacturers: All

exact submission · checked 2026-09-01

Confirm currently supported software versions, protocols, and site-specific acquisition configurations.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for DeepTek CXR Analyzer v1.0; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-09
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K231001
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
X-ray/Radiography
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Anatomy
Chest: lungs, pleura, cardiac structures, and hardware
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2023-10-05
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
26Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission

    No public price or quote for the exact K231001 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-09 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-09 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

8 sources - 3 history items

Source ledger

  1. FDA K231001: DeepTek CXR Analyzer v1.0

    U.S. Food and Drug Administration - Published 2023-10-05 - Accessed 2026-09-09

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, deployment

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. DeepTek CXR analyzer v1.0 model card (K231001)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, limitations, reportedSensitivity, reportedSpecificity, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K231001

    U.S. Food and Drug Administration - Accessed 2026-09-09

    Scope: postmarketSafety

  8. DeepTek: Regulatory

    DeepTek - Accessed 2026-10-27

    Scope: security

Research history

  1. K231001 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K251934

qXR-Detect

Qure.Ai Technologies

Authorized purpose: qXR-Detect is an adult chest-radiograph concurrent reading aid that identifies, highlights and categorizes suspicious regions of interest across lung, pleura, mediastinum/hila/heart, bone, hardware and other categories; trained clinicians remain responsible for primary interpretation.

Modality
X-ray/Radiography
Anatomy
Chest/Lung; pleura, mediastinum/hila/heart, bone, hardware and other chest-radiograph regions
Decision
2026-01-16
FDA-cleared K210666

Chest-CAD

Imagen Technologies, Inc

Authorized purpose: Concurrent CADe reading aid that identifies, categorizes, and highlights suspicious regions of interest on adult chest radiographs

Modality
X-ray/Radiography
Anatomy
Chest/thorax, with ROI categories covering cardiac, mediastinum/hila, lungs, pleura, bones, soft tissues, hardware, and other
Decision
2021-07-20
FDA-cleared K252953

Velmeni for Dentists (V4D) Endo-Perio

Velmeni, Inc.

Authorized purpose: Concurrent-read CADe to assist dentists in detecting specified tooth and jaw anatomy, bone-level landmarks, and root-canal-treated teeth in digital radiographs of permanent teeth in patients 15 years or older.

Modality
X-ray/Radiography
Anatomy
Permanent teeth and jaw/maxillofacial anatomy, including enamel, dentine, pulp, root, mental foramen, inferior alveolar canal, maxillary sinus, cementoenamel junction, crestal bone, and root-canal-treated teeth
Decision
2026-05-11
FDA-cleared K253502

Critical Care Suite with Enteric Tube Positioning AI Algorithm

Ge Medical Systems, LLC

Authorized purpose: Analyze frontal chest and abdominal X-ray images to detect and localize a nasally or orally inserted enteric tube, its tip and side port if present, and the diaphragm and airways for radiologist review.

Modality
X-ray/Radiography
Anatomy
Chest/lung and abdomen/stomach; enteric tube, tube tip and side port, diaphragm, and airways including carina and left/right bronchi
Decision
2026-04-14

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history